AM251 suppresses the viability of HepG2 cells through the AMPK (AMP-activated protein kinase)-JNK (c-Jun N-terminal kinase)-ATF3 (activating transcription factor 3) pathway

Citations

WEB OF SCIENCE

25
Citations

SCOPUS

27

초록

AM251, a cannabinoid antagonist, has various biological activities. In this study, we found that AM251 suppressed the viability of hepatoma HepG2 cells and also increased phosphorylation of JNK (c-jun N-terminal kinase) and ATF3 (activating transcription factor 3). In addition, AM251 phosphorylated AMPK (AMP-activated protein kinase) in a time and dose-dependent manner. Inhibition of AMPK blocked AM251-induced JNK/ATF3 phosphorylation. Expression of AMPK or treatment with AICAR (5-aminoimidazole-4-carboxy-amide-1-D-ribofuranoside), an AMPK activator, activated the JNK/ATF3 pathways. Together, these results suggest that AM251 may have anti-tumor effects in hepatoma through activation of the AMPK-JNK-ATF3 signal pathway. (c) 2008 Published by Elsevier Inc.

키워드

AMPK; AM251; cannabinoid antagonist; JNK; ATF3; CANNABINOID SYSTEM; ENERGY-BALANCE; CANCER CELLS; FOOD-INTAKE; KEY SENSOR; APOPTOSIS; ATF3
제목
AM251 suppresses the viability of HepG2 cells through the AMPK (AMP-activated protein kinase)-JNK (c-Jun N-terminal kinase)-ATF3 (activating transcription factor 3) pathway
저자
Lee, Yun Mi; Uhm, Kyung-Ok; Lee, Eun Soo; Kwon, Joseph; Park, Sun Hwa; Kim, Hyeon Soo
DOI
10.1016/j.bbrc.2008.04.003
발행일
2008-06
유형
Article
저널명
Biochemical and Biophysical Research Communications
권
370
호
4
페이지
641 ~ 645